-- Addresses the introduction of Betaseron as the first drug approved by the FDA for treatment of some patients with MS-- Assesses the results of new clinical trials with other interferons, Cop-1, and oral myelin-- Contains expanded information on the use of antidepressants, such as Prozac, to combat psychological effects-- Discusses laws that help individuals with MS avoid discrimination in employment-- Outlines recent findings in epidemiology and genetics-- Includes patient resources